Research Analysts Issue Forecasts for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Xenon Pharmaceuticals in a research note issued on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now expects that the biopharmaceutical company will earn ($3.85) per share for the year, down from their prior estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($4.08) EPS.

Several other equities research analysts have also recently issued reports on the stock. Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday. Evercore ISI initiated coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They set an “outperform” rating and a $55.00 price target on the stock. Wedbush raised their price target on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $53.20.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $37.96 on Thursday. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00. The stock has a market capitalization of $2.93 billion, a P/E ratio of -10.69 and a beta of 1.16. The firm’s 50-day moving average is $32.46 and its two-hundred day moving average is $34.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.04). During the same quarter in the previous year, the business earned ($0.75) EPS.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC purchased a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals in the first quarter valued at approximately $30,000. Elevation Point Wealth Partners LLC purchased a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $32,000. GF Fund Management CO. LTD. purchased a new position in Xenon Pharmaceuticals in the fourth quarter valued at approximately $63,000. Finally, Quarry LP purchased a new position in Xenon Pharmaceuticals in the fourth quarter valued at approximately $78,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.